

## PDVAC virtual session on “VIPS” 8 July 2020

## PDVAC COMMITTEE MEMBERS

**Klaus Cichutek** (*apologies*)Substitute: **Isabelle Bekerredjian-Ding**

Paul-Ehrlich-Institute (PEI)

Langen, Germany

[klaus.cichutek@pei.de](mailto:klaus.cichutek@pei.de)[Isabelle.Bekerredjian-Ding@pei.de](mailto:Isabelle.Bekerredjian-Ding@pei.de)**Sinead Delany-Moretlwe**

University of Witwatersrand (Wits)

Johannesburg, South Africa

[sdelany@wrhi.ac.za](mailto:sdelany@wrhi.ac.za)**Bernard Fritzell** (*apologies*)

Independent

Bordeaux, France

[bernardfritzell@hotmail.fr](mailto:bernardfritzell@hotmail.fr)**Barney Graham** (*apologies*)

NIAID, Vaccine Research Center

Bethesda, USA

[bgraham@mail.nih.gov](mailto:bgraham@mail.nih.gov)**Gagandeep Kang** (*apologies*)

Christian Medical College

Vellore, India

[gkang@cmcvellore.ac.in](mailto:gkang@cmcvellore.ac.in)**Ruth Karron**

Johns Hopkins Bloomberg School of Public Health

(JHSPH)

Baltimore, USA

[rkarron@jhsp.edu](mailto:rkarron@jhsp.edu)**David Kaslow (CHAIR)**

PATH

Seattle, USA

[dkaslow@path.org](mailto:dkaslow@path.org)**Jerome Kim**

International Vaccine Institute (IVI)

Seoul, Korea

[Jerome.Kim@ivi.int](mailto:Jerome.Kim@ivi.int)**Claudio Lanata**

Instituto de Investigación Nutricional

Lima, Peru

[clanata@iin.sld.pe](mailto:clanata@iin.sld.pe)**Shabir Madhi** (*apologies*)

Witwatersrand University

Johannesburg, South Africa

[madhis@rmpru.co.za](mailto:madhis@rmpru.co.za)

**Beno Y. Nyam**

National Agency for Food and Drug Administration and  
Control  
Lagos, Nigeria

[beno.y@nafdac.gov.ng](mailto:beno.y@nafdac.gov.ng)

**Mark Papania**

Centers for Disease Control and Prevention  
Atlanta, USA

[myp7@cdc.gov](mailto:myp7@cdc.gov)

**Peter Smith**

London School of Hygiene and Tropical Medicine  
London, UK

[Peter.Smith@lshtm.ac.uk](mailto:Peter.Smith@lshtm.ac.uk)

**Yiming Shao**

Chinese Center for Disease Control and Prevention  
(CDC)  
Beijing, China

[yshao@bjmu.edu.cn](mailto:yshao@bjmu.edu.cn)

**Marian W. Wentworth (apologies)**

Management Sciences for Health (MSH)  
Medford, USA

[mwentworth@msh.org](mailto:mwentworth@msh.org)

---

## OBSERVERS

**Jean-Pierre Amorij**  
UNICEF Supply Division  
Copenhagen, Denmark

[jamorij@unicef.org](mailto:jamorij@unicef.org)

**Annaliesa Anderson**  
Pfizer  
USA

[Annaliesa.Anderson@pfizer.com](mailto:Annaliesa.Anderson@pfizer.com)

**Robin Biellik**  
Independent

[rbiellik@gmail.com](mailto:rbiellik@gmail.com)

**Jeff Blue**  
Merck  
West Point, USA

[jeff\\_blue@merck.com](mailto:jeff_blue@merck.com)

**Holly Clifford**  
EpiVax  
Providence, USA

[hclifford@epivax.com](mailto:hclifford@epivax.com)

**Alejandro Cravioto**  
University of Mexico  
Puerto Vallarta, Mexico

[dracravioto@hotmail.com](mailto:dracravioto@hotmail.com)

**Niklas Danielsson**  
UNICEF  
Copenhagen, Denmark

[ndanielsson@unicef.org](mailto:ndanielsson@unicef.org)

**Kristen Earle**  
Bill & Melinda Gates Foundation  
Seattle, USA

[Kristen.Earle@gatesfoundation.org](mailto:Kristen.Earle@gatesfoundation.org)

**Rebecca Fields**  
John Snow, Inc.  
Washington DC, USA

[rebecca\\_fields@jsi.com](mailto:rebecca_fields@jsi.com)

**Michael Free**  
Independent

[mfree@wavecable.com](mailto:mfree@wavecable.com)

**Collrane Frivold**  
PATH  
Seattle, USA

[cfrivold@path.org](mailto:cfrivold@path.org)

**Julian Hickling**  
Working in Tandem Ltd  
Cambridge, UK

[julian@workingintandem.co.uk](mailto:julian@workingintandem.co.uk)

**Courtney Jarrahan**

PATH

Seattle, USA

[cjarrahan@path.org](mailto:cjarrahan@path.org)

**Vibhu Kanchan**

Hilleman Laboratories

New Delhi, India

[vibhu.kanchan@hillemanlabs.org](mailto:vibhu.kanchan@hillemanlabs.org)

**Susan King**

Vaccines, GSK

Wavre, Belgium

[sue.a.king@gsk.com](mailto:sue.a.king@gsk.com)

**Ingrid Kromann**

CEPI

Oslo, Norway

[ingrid.kromann@cepi.net](mailto:ingrid.kromann@cepi.net)

**Joe Little**

PATH,

Seattle, USA

[jlittle@path.org](mailto:jlittle@path.org)

**Mandu Madan**

Hilleman Laboratories

New Delhi, India

[madhu.madan@hillemanlabs.org](mailto:madhu.madan@hillemanlabs.org)

**Carsten Mantel**

MMGH Global Health Consulting

Berlin, Germany

[mantelc@mmglobalhealth.org](mailto:mantelc@mmglobalhealth.org)

**Marion Menozzi-Arnaud**

GAVI, the Vaccine Alliance

Geneva, Switzerland

[mmenozziarnaud@gavi.org](mailto:mmenozziarnaud@gavi.org)

**Jules Millogo**

Merck

West Point, USA

[jules.millogo@merck.com](mailto:jules.millogo@merck.com)

**Nitin Mittal**

Hilleman Laboratories

New Delhi, India

[nitin.mittal@hillemanlabs.org](mailto:nitin.mittal@hillemanlabs.org)

**Kelly Moore**

Vanderbilt School of Medicine

Nashville, USA

[drkellymoore@yahoo.com](mailto:drkellymoore@yahoo.com)

**William Moss**

Johns Hopkins Bloomberg School of Public Health

Baltimore, USA

[wmoss1@jhu.edu](mailto:wmoss1@jhu.edu)

**Mercy Mvundura**

PATH,

Seattle, USA

[mmvundura@path.org](mailto:mmvundura@path.org)

**David Robinson**  
Bill & Melinda Gates Foundation  
Seattle, USA

[David.Robinson@gatesfoundation.org](mailto:David.Robinson@gatesfoundation.org)

**James Robinson**  
Independent

[james\\_m.robinson@outlook.com](mailto:james_m.robinson@outlook.com)

**Nitin Saigal**  
Hilleman Laboratories  
New Delhi, India

[nitin.saigal@hillemanlabs.org](mailto:nitin.saigal@hillemanlabs.org)

**Barbara Saitta**  
Medecins Sans Frontieres  
New York, USA

[Barbara.Saitta@newyork.msf.org](mailto:Barbara.Saitta@newyork.msf.org)

**Louise Saldutti**  
Merck  
New Jersey, USA

[louise\\_saldutti@merck.com](mailto:louise_saldutti@merck.com)

**Hardeep Sandhu**  
CDC  
Atlanta, USA

[hjs3@cdc.gov](mailto:hjs3@cdc.gov)

**Xin Tong**  
Walvax  
Kunming, Yunnan Province, China

[xin.tong@walvax.com](mailto:xin.tong@walvax.com)

**Ted Tsai**  
Takeda  
Cambridge, USA

[Ted.Tsai@takeda.com](mailto:Ted.Tsai@takeda.com)

**Lingjiang Yang**  
Sinopharm  
Sichuan, China

[yanglingjiang@sinopharm.com](mailto:yanglingjiang@sinopharm.com)

**Jayanthi Wolf**  
Merck  
New Jersey, USA

[jayanthi\\_wolf@merck.com](mailto:jayanthi_wolf@merck.com)

**Andrew Wong**  
Walvax  
Kunming, Yunnan Province, China

[andrew.wong@walvax.com](mailto:andrew.wong@walvax.com)

**Neal Xiao**  
Walvax  
Kunming, Yunnan Province, China

[neal.xiao@walvax.com](mailto:neal.xiao@walvax.com)

<b>WHO HQ SECRETARIAT</b>
---------------------------

**Bernadette Abela Ridder**, Scientist, Public Health, Vector Control and Environment

**Mohammed Alali**, Technical Officer, Vaccines & Immunization Devices Assessment

**Natasha Crowcroft**, Agenda, Policy & Strategy, IVB

**Ronaldo Dominguez Morales**, Scientist, Vaccines & Immunization Devices Assessment

**Martin Friede**, Unit Head, Vaccine Product & Delivery Research, IVB

**Birgitte Giersing**, Team Lead (a.i.), Vaccine Prioritization and Platforms, Vaccine Product & Delivery Research, IVB

**Mateusz Hasso-Agopsowicz**, Consultant, Vaccine Product & Delivery Research, IVB

**Richard Isbrucker**, Scientist, Norms and Standards for Biological Products

**Anna-lea Kahn**, Technical Officer, Vaccine Product & Delivery Research, IVB

**Hye-Na Kang**, Scientist, Norms and Standards for Biological Products

**Lea Knopf**, Consultant, Public Health, Vector Control and Environment

**Zuma Munkombwe**, Technical Officer, Vaccines & Immunization Devices Assessment

**Samir Sodha**, Technical Officer, Essential Programme on Immunization, IVB

**Erin Sparrow**, Technical Officer, Vaccine Prioritization and Platforms, Vaccine Product & Delivery Research, IVB